The Centers for Disease Control and Prevention this week health care providers and others to a continued increase in opioid overdose deaths involving fentanyl and its analogs. Among other increases, the number of overdose deaths involving the analog carfentanil, 100 times more potent than fentanyl, nearly doubled in the first half of 2017 in the 10 states reporting preliminary data to CDC, to 815. Health care providers may need to administer multiple doses of naloxone per overdose due to the increased potency of these drugs relative to other opioids, the agency said. 鈥淥rally-ingested counterfeit pills laced with fentanyl or fentanyl analogs may require prolonged dosing of naloxone in the [emergency department] hospital setting due to a delayed toxicity that has been reported in some cases,鈥 the advisory notes. CDC recommends that health care providers discuss treatment options with patients who have opioid use disorders and opioid-related overdoses, once stabilized. Post-overdose protocols include prescribing naloxone and connecting patients with case management services or peer navigators to help link them to treatment services, CDC said. In other news, Attorney General Jeff Sessions yesterday an initiative to reduce the supply of illicit synthetic opioids, including fentanyl and fentanyl analogs.

Related News Articles

Headline
The National Institutes of Health April 3 released a study that found an artificial intelligence screening tool was as effective as health care providers in鈥
Headline
The Department of Health and Human Services March 18 announced that it renewed the public health emergency for the nation鈥檚 opioid crisis an additional 90 days鈥
Headline
The Department of Health and Human Services Office of Inspector General Feb. 18 released a report that found about 40% of Medicare enrollees who began opioid鈥
Headline
Today the Drug Enforcement Administration and Department of Health and Human Services announced that the effective date for the final rule regarding鈥
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to鈥
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,鈥